DUBLIN – Celyad SA became the eighth European firm to complete an IPO on Nasdaq this year, grossing $100 million in an offering that bridged the Atlantic, but the celebrations were cut short by a temporary halt in trading on the Euronext Exchange in Brussels late afternoon local time Friday, as the stock dropped 12 percent in response to a weak opening on Wall Street. Read More
PHILADELPHIA – With biotech enjoying a spurt of tremendous growth – increasing market caps and widening profit margins – another trend has emerged, one that’s not quite so enjoyable, at least for company execs: increasingly confrontational shareholder activity. Read More
HONG KONG – Claims last year that the Chinese market was due for a massive exodus, particularly in the biotech space, may have been somewhat premature. Both international and domestic investors are actively betting on the country’s pharmaceutical sector. Read More
TAIPEI, Taiwan – Translational science specialist BRIM Biotechnology Inc. has entered a collaboration agreement with Janssen Pharmaceutica N.V., a unit of Johnson & Johnson, for research, development and commercialization of compounds identified by Janssen for dengue fever indications. Read More
Researchers have reported success in understanding why some attempts to vaccinate against mucosal pathogens have backfired, leading to worse disease instead of protecting the vaccines. Read More
Predicting human response to therapeutics long before mounting costs inhibit the science is a menacing challenge faced by researchers historically dependent on cell cultures and animal models to generate often unreliable data. Read More
Provectus Biopharmaceuticals Inc., of Knoxville, Tenn., priced an underwritten public offering of 17.5 million common shares and warrants to purchase another 17.5 million common shares at a price of 75 cents for a fixed unit of one common share plus a warrant to purchase an additional common share. Read More
Can-Fite Biopharma Ltd. subsidiary Ophthalix Inc., of Petach Tikva, Israel, has signed a definitive agreement to acquire Israel-based Improved Vision Systems Ltd. (IVS), a company developing medical device technologies to improve sight, diagnose and offer therapy for a variety of ocular diseases including glaucoma, age-related macular degeneration, diabetic retinopathy and oculo-motor pathologies. Read More
Tekmira Pharmaceuticals Corp. shares (NASDAQ:TKMR) fell $1.74, or 11.6 percent, to close at $13.28 after the Vancouver, British Columbia-based company said that an open-label, single-arm phase II study of TKM-Ebola-Guinea had reached a predefined statistical endpoint and enrollment had been closed. Read More
Applied Genetic Technologies Corp., of Gainesville, Fla., appointed Mark S. Shearman chief scientific officer and Rabia Ozden vice president of clinical research and development. Read More
